Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial

Bitget2026/09/18 12:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers.
All participating sites also secured IRB sign-off, clearing the way to start patient enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY51161) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial

You may also like

Crypto prices